This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returne…

Relapsed/Refractory Systemic Light Chain Amyloidosis

~Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT06292780

Phase 1

A Phase 1b/2 Study of AZD0120 (Also Known as GC012F), a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B Cell Maturation Antigen in Participants With Relapsed or Refractory AL Amyloidosis.

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light cha…

Relapsed AL AmyloidosisRefractory AL AmyloidosisLight Chain Amyloidosis+1 more

~Estimated

~$10 – $8,750

Alexion Pharmaceuticals, Inc.NCT07081646